SCHEDULE 14A
                    Proxy Statement Pursuant to Section 14(a)
            of the Securities Exchange Act of 1934 (Amendment No. __)


Filed by the Registrant                     [ ]

Filed by a Party other than the Registrant  [x]

Check the appropriate box:

[ ]  Preliminary Proxy Statement
[ ]  Confidential, for Use of the Commission Only (as permitted by
     Rule 14a-6(e)(2))
[ ]  Definitive Proxy Statement
[X]  Definitive Additional Materials
[ ]  Soliciting Material Pursuant to ss. 240.14a-12

                                Biogen Idec Inc.
                (Name of Registrant as Specified In Its Charter)

                                  Carl C. Icahn
                               Alexander J. Denner
                               Richard C. Mulligan
                                 Thomas F. Deuel
                                 David Sidransky
                                    Mayu Sris
                                    Eric Ende
                                 Jeffrey Meckler
                                Icahn Partners LP
                          Icahn Partners Master Fund LP
                        Icahn Partners Master Fund II LP
                        Icahn Partners Master Fund III LP
                         High River Limited Partnership
                                 Barberry Corp.
                             Hopper Investments LLC
                                Icahn Offshore LP
                                Icahn Onshore LP
                                Icahn Capital LP
                                   IPH GP LLC
                         Icahn Enterprises Holdings L.P.
                           Icahn Enterprises G.P. Inc.
                                  Beckton Corp.
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (check the appropriate box):

[X] No fee required.

[ ] Fee computed on table below per Exchange Act Rule 14a-6(i)(4) and 0-11.

    1) Title of each class of securities to which transaction applies:

    2) Aggregate number of securities to which transaction applies:

    3) Per unit price or other  underlying  value of  transaction  computed
pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee
is calculated and state how it was determined):

    4) Proposed maximum aggregate value of transaction:

    5) Total fee paid:

[ ] Fee paid previously with preliminary materials.

[ ] Check box if any part of the fee is offset as provided by Exchange  Act Rule
    0-11(a)(2)  and  identify  the  filing  for  which the  offsetting  fee was
    paid previously.  Identify the previous filing by registration  statement
    number, or the Form or Schedule and the date of its filing.

    1) Amount Previously Paid:

    2) Form, Schedule or Registration Statement No.:

    3) Filing Party:

    4) Date Filed:





On May 21,  2009,  Dr.  Alexander  J. Denner and Dr.  Richard C.  Mulligan  were
elected  to  the  Board  of   Directors  of  Enzon   Pharmaceuticals,   Inc.,  a
biopharmaceutical company.


ON MAY 15, 2009, THE  PARTICIPANTS  FILED A DEFINITIVE  PROXY STATEMENT WITH THE
SECURITIES  AND EXCHANGE  COMMISSION.  SECURITY  HOLDERS ARE ADVISED TO READ THE
PROXY  STATEMENT AND OTHER DOCUMENTS  RELATED TO THE  SOLICITATION OF PROXIES BY
CARL C. ICAHN, ALEXANDER J. DENNER, RICHARD C. MULLIGAN,  THOMAS F. DEUEL, DAVID
SIDRANSKY,  MAYU SRIS,  ERIC ENDE,  JEFFREY  MECKLER,  ICAHN  PARTNERS LP, ICAHN
PARTNERS MASTER FUND LP, ICAHN PARTNERS MASTER FUND II LP, ICAHN PARTNERS MASTER
FUND III LP, HIGH RIVER LIMITED PARTNERSHIP, BARBERRY CORP. , HOPPER INVESTMENTS
LLC,  ICAHN  OFFSHORE LP, ICAHN ONSHORE LP, ICAHN CAPITAL LP, IPH GP LLC,  ICAHN
ENTERPRISES   HOLDINGS  L.P.  ,  ICAHN  ENTERPRISES  G.P.  INC.,  BECKTON  CORP.
(COLLECTIVELY,  THE "PARTICIPANTS")  AND CERTAIN OF THEIR RESPECTIVE  AFFILIATES
FROM THE STOCKHOLDERS OF BIOGEN IDEC INC. FOR USE AT ITS ANNUAL MEETING, BECAUSE
THEY  CONTAIN  IMPORTANT  INFORMATION,  INCLUDING  INFORMATION  RELATING  TO THE
PARTICIPANTS  IN THE PROXY  SOLICITATION.  THE DEFINITIVE  PROXY STATEMENT AND A
FORM OF PROXY  ARE  AVAILABLE  TO  STOCKHOLDERS  OF BIOGEN  IDEC  INC.  FROM THE
PARTICIPANTS  AT NO CHARGE AND ARE ALSO AVAILABLE AT NO CHARGE AT THE SECURITIES
AND EXCHANGE  COMMISSION'S WEBSITE AT  HTTP://WWW.SEC.GOV  OR BY CONTACTING D.F.
KING & CO., INC. BY TELEPHONE TOLL FREE AT 1 (800) 769-4414.